Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS2R14 | Q9NYV8 | 4/20 | 0.64 |
| ▸ | MEN1 | O00255 | 2/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.64 |
| ▸ | DAGLA | Q9Y4D2 | 3/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.63 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.55 |
| ▸ | CNR2 | P34972 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15705635 | 0.91 | DAGLA (0.71) | TAS2R14MEN1KMT2ADAGLAALDH1A1 | |
| SCHEMBL5191217 | 0.89 | TAS2R14 (0.71) | TAS2R14MEN1KMT2ADAGLAALDH1A1 | |
| SCHEMBL5092519 | 0.85 | KEAP1 (0.81) | TAS2R14DAGLAALDH1A1KEAP1CNR2 | |
| SCHEMBL5899440 | 0.85 | TAS2R14 (0.63) | TAS2R14MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL984791 | 0.85 | TAS2R14 (0.71) | TAS2R14MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL2845552 | 0.84 | MEP1B (0.68) | TAS2R14MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL11802279 | 0.84 | MAPK1 (0.71) | DAGLAALDH1A1KEAP1MAPK1 | |
| SCHEMBL4540959 | 0.83 | MEN1 (0.64) | TAS2R14MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL6421016 | 0.82 | CA2 (0.53) | TAS2R14MEN1KMT2ADAGLAALDH1A1 | |
| SCHEMBL22142471 | 0.81 | HDAC6 (0.64) | TAS2R14DAGLAALDH1A1KEAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9757375-B2 | Compounds that inhibit human DNA ligases and methods of treating cancer | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2017-09-12 | — | — | US | disclosed |
| US-7659293-B2 | α-Amino-N-hydroxy-acetamide derivatives | NOVARTIS AG (CH) | 2010-02-09 | — | — | US | disclosed |
| US-20080176916-A1 | A-AMINO-N-HYDROXY-ACETAMIDE DERIVATIVES | NOVARTIS AG (CH) | 2008-07-24 | — | — | US | disclosed |
| US-7291634-B2 | α-amino-N-hydroxy-acetamide derivatives | NOVARTIS AG (CH) | 2007-11-06 | — | — | US | disclosed |
| WO-2007001335-A2 | RAMOPLANIN DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | VICURON PHARMACEUTICALS INC. (US) | 2007-01-04 | — | — | WO | disclosed |
| US-20060211603-A1 | Ramoplanin derivatives possessing antibacterial activity | VICURON PHARMACEUTICALS INC. (US) | 2006-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176916-A1 | A-AMINO-N-HYDROXY-ACETAMIDE DERIVATIVES | MMP1, MMP9, MMP14 | TAS2R14 2946/4885MEN1 2777/4885KMT2A 410/4885 |
| US-20060211603-A1 | Ramoplanin derivatives possessing antibacterial activity | CLSPN, LMAN2, RPN2 | TAS2R14 1542/4885MEN1 2853/4885KMT2A 4422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.